Welcome to EMPOWERED

PNH Essentials 2025-2026: Participant Poll 3

Answer the following polling question to share your perspectives with the PNH Essentials expert panel and your peers.

This poll closes on Thursday 19 February 2026. Answers to these questions will be addressed in PNH Essentials video episode 4, which will be released in February 2026. Aggregated, deidentified results will be shared with the expert panel for discussion at the live online event on 26 March 2026.

1. How do you define/characterise the presence of breakthrough haemolysis (BTH) in patients with PNH treated with complement inhibition therapy?

(select all that apply)

Lactate dehydrogenase above normal

Appearance of a thrombotic event

Shortness of breath

Lactate dehydrogenase > 2 x upper limit of normal

Abdominal pain

Presence of a complement-activating condition (e.g. infection, inflammation)

Sudden reappearance of haemoglobinuria (dark urine)

Decrease in haemoglobin level of more than 20 g/L

I don’t know / I don’t have clinical experience in managing BTH/PNH